Icos spin-off Calistoga gets $21mm in Series A; adds $5.2mm
Executive Summary
Calistoga Pharmaceuticals (cancer and inflammatory diseases) raised $21mm through its Series A venture round led by Frazier Healthcare Ventures and including Alta Partners, Three Arch Ventures, Amgen Ventures, and Eli Lilly.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice